Antidiabetic drug effects on gastrointestinal health: convergent evidence from a longitudinal cohort and Mendelian randomization study - PubMed
19 hours ago
- #Antidiabetic drugs
- #Mendelian randomization
- #Gastrointestinal health
- Sulfonylurea use is associated with a lower risk of colorectal cancer (CRC) compared to non-sulfonylurea users (HR: 0.76).
- Insulin use is linked to a decreased risk of diverticular disease versus non-insulin users (HR: 0.75).
- Combination therapy of metformin with sulfonylureas further reduces CRC risk (HR: 0.61).
- Post-metformin use of DPP-4 inhibitors with sulfonylureas or GLP-1 receptor agonists increases acute pancreatitis risk.
- Mendelian randomization validates that sulfonylureas targeting INS reduce CRC risk (OR: 0.56) and insulin targeting LRP2 reduces diverticular disease risk (OR: 0.89).
- Antidiabetic regimens, including combinations and sequences, are clinically important for preventing gastrointestinal morbidity in type 2 diabetes patients, highlighting the need for personalized treatment.